Characterization of Coagulation Factor-platelet Interactions: Role of FXI
Characterization of Coagulation Factor-platelet Interactions: Role of FXI
批准号:
10133119
负责人:
Owen J McCarty
金额:
$70.07万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-15 至 2023-03-31
关键词:
AddressAdhesionsAnimal ModelAnti-Cytokine TherapyAnti-Inflammatory AgentsAntibodiesAnticoagulantsAntiplatelet DrugsAntisense OligonucleotidesArterial Fatty StreakArteriesArteriosclerosisArthritisAtherosclerosisAttenuatedBindingBiomedical ResearchBloodBlood Coagulation FactorBlood PlateletsBlood ProteinsBlood VesselsBlood coagulationBradykininCardiovascular DiseasesCardiovascular systemCell CommunicationCessation of lifeChronicComplementComplement ActivationComplexCountryDataDedicationsDepositionDevelopmentDisease modelEndothelial CellsEndotheliumEventExperimental ModelsFactor XIFactor XI DeficiencyFactor XIIGenerationsGoalsGrantHeart failureHemorrhageHemostatic functionHumanHypertensionIn VitroIncidenceIndustrializationInfiltrationInflammationInflammatoryKininogenaseLeukocyte TraffickingLeukocytesLinkMediatingModelingMolecular TargetMusMyocardial InfarctionPathogenesisPathologicPathologic ProcessesPathway interactionsPatientsPharmacologyPhysiologicalPlasminogen Activator Inhibitor 1Platelet ActivationPlatelet Count measurementPlatelet InhibitorsPrimatesProteinsResearchResolutionRiskRoleSafetyScheduleSerpinsSeveritiesSignal TransductionStrokeSystemSystemic Inflammatory Response SyndromeTFPITestingThrombinThrombopoietinThrombosisThrombusTranslatingTranslationsUltrasonographyWorkatherogenesiscirculating biomarkerscontrast enhancedcytokineendothelial dysfunctiongenetic risk factorgranulocyteimaging platformin vivoinflammatory markerinhibitor/antagonistmigrationmolecular imagingmonocytemortalitynew therapeutic targetnonhuman primatenovelphase II trialpreventprogramsrecruitresponsethrombotictooltraditional therapytreatment riskvascular inflammation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary:
Atherosclerosis remains the underlying cause of the majority of cardiovascular diseases contributing to
mortality. Our overall hypothesis is that pathological activation of two blood contact system proteins, factor
(F) XI and FXII, mediate platelet-endothelial interactions to promote inflammation and leukocyte trafficking
in experimental models of atherosclerotic plaque formation. Our preliminary studies linking contact
activation to inflammation and platelet activation suggest that pharmacological targeting of FXI could
reduce vascular inflammation, atherogenesis, and its cardiovascular complications, and would be safer
than traditional anticoagulants or platelet inhibitors, which carry a significant risk of fatal bleeding.
Our work and findings to date have opened the window towards the development of safer antithrombotic
strategies. This program will take a new direction to study whether contact activation increases platelet-
endothelial cell interactions, leukocyte recruitment and infiltration, and inflammation to promote
atherosclerotic plaque formation. This program will build on our ability to develop tools for molecular
imaging of cell interactions, the creation of novel inhibitors of contact activation, and rational and
responsible use of and translation from in vitro studies to in vivo mouse and non-human primate models of
disease. In Aim 1 we will determine the role of FXI in activating platelets to promote atherogenesis. We will
test our hypothesis that FXI-dependent platelet activation promotes recruitment of leukocytes to inflamed
endothelium. In Aim 2 we will determine the role of FXII in promoting inflammation in atherogenesis. We
will test our hypothesis that FXII activation of and by FXI induces cytokine and complement generation
that contribute to inflammation to promote atherogenesis. We will translate our mechanistic in vitro studies
to define the pathological role of contact activation in 2 distinct animal models of atherogenesis.
The translational relevance of our project will be the potential identification of safe molecular targets and
mechanisms that could support the development of novel pharmacological approaches to address the
problem of progressive atherosclerosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterization of Coagulation Factor-platelet Interactions: Role of FXI
-
批准号:9381316
-
项目类别:
-
资助金额:$1.51万
-
财政年份:2017
-
负责人:Owen J McCarty
-
依托单位:
Characterization of coagulation factor-platelet interactions: role of FXI
-
批准号:8244436
-
项目类别:
-
资助金额:$37.01万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of coagulation factor-platelet interactions: role of FXI
-
批准号:9241431
-
项目类别:
-
资助金额:$44.3万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of coagulation factor-platelet interactions: role of FXI
-
批准号:7992464
-
项目类别:
-
资助金额:$37.4万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of coagulation factor-platelet interactions: role of FXI
-
批准号:9041656
-
项目类别:
-
资助金额:$38.31万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of coagulation factor-platelet interactions: role of FXI
-
批准号:8478017
-
项目类别:
-
资助金额:$7.21万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of Coagulation Factor-platelet Interactions: Role of FXI
-
批准号:9764125
-
项目类别:
-
资助金额:$70.76万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of coagulation factor-platelet interactions: role of FXI
-
批准号:8644856
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of Coagulation Factor-platelet Interactions: Role of FXI
-
批准号:10386792
-
项目类别:
-
资助金额:$70.11万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of coagulation factor-platelet interactions: role of FXI
-
批准号:8449717
-
项目类别:
-
资助金额:$43.44万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of coagulation factor-platelet interactions: role of FXI
-
批准号:8106274
-
项目类别:
-
资助金额:$37.39万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
Characterization of coagulation factor-platelet interactions: role of FXI
-
批准号:8906641
-
项目类别:
-
资助金额:$38.31万
-
财政年份:2010
-
负责人:Owen J McCarty
-
依托单位:
海外基金